New sickle cell gene therapies are a breakthrough, but solving how to pay their high prices is a struggle
Breakthrough sickle cell treatments are available in the U.S., but their high cost is forcing insurers to get creative. Source
Read MoreBreakthrough sickle cell treatments are available in the U.S., but their high cost is forcing insurers to get creative. Source
Read MoreHere are the biggest calls on Wall Street on Source link
Read MoreNames on the move ahead of the open. Source link
Read MoreThese names had short positions amounting to at least 25% of their total float at the end of March, according
Read MoreBaird initiated coverage of bluebird bio with an outperform rating and $10 price target, which implies 104% upside from Monday's
Read More